Global Prescription Drug Costs: Why We Need Differential Pricing

Posted by Ed Schoonveld on Wed, Dec 18, 2019

The Trump administration is not the first government to explore the use of international price referencing to force drug prices down. This usually involves the institution of a price ceiling based on an average price for the same drug in a “basket” of other countries. The basket is supposed to consist of countries with similar income levels, but oftentimes that’s not actually the case. That’s just one of the many problems with international price referencing laws.


>
Read More

Accelerating Market Access: Three Trends Shaping Pharma’s Future

Posted by Ed Schoonveld on Mon, Dec 16, 2019

Dean Hakanson co-wrote this blog post with Ed Schoonveld.

Is the demand for value-based care merely superficial? Are the industry’s decision-making and incentive systems built to encourage clinical innovation? How will pharma companies rethink their pipelines to improve poor commercialization efforts?


>
Read More

The Benefits and Misconceptions of Indication-Based Pricing

Posted by Ed Schoonveld on Fri, Jul 21, 2017

A recent Wall Street Journal article raised the challenge related to Novartis’ high-cost orphan drug Ilaris, which may have clinical potential in a broader use as a cardiovascular drug. For the cardiovascular use, the company would have to charge a significantly lower price to gain adoption in the market. It’s a fairly extreme example of a common situation where drugs with potential uses in different indications, different population sizes and different competitive price levels are posing a tough dilemma for the drug company. Indication-based pricing, allowing for a different price across diseases treated, would provide a solution to this problem and would, in some cases, allow for earlier and broader patient availability of new prescription drug treatments.


>
Read More

Brexit’s Impact on the EU’s Drug-Pricing Climate

Posted by Ed Schoonveld on Thu, Jun 30, 2016


Surprised and stunned by the U.K’s vote last Friday to exit the European Union, the world is experiencing a collective panic. However, currency and stock devaluations have mainly been driven by uncertainty rather than solid projections of corporate performance gaps, all of which has been further enhanced and inflamed by the media in their constant quest for better ratings.


>
Read More

Clinton on Drug-Pricing Warpath: Populism, Real Problem or Both?

Posted by Ed Schoonveld on Mon, Jan 11, 2016

When pointing a finger at someone, usually three fingers are pointed at yourself. U.S. government and presidential candidates should consider this before they rush to the media briefing rooms.


>
Read More